| Autor: |
Sanij, Elaine, Hannan, Katherine M., Xuan, Jiachen, Yan, Shunfei, Ahern, Jessica E., Trigos, Anna S., Brajanovski, Natalie, Son, Jinbae, Chan, Keefe T., Kondrashova, Olga, Lieschke, Elizabeth, Wakefield, Matthew J., Frank, Daniel, Ellis, Sarah, Cullinane, Carleen, Kang, Jian, Poortinga, Gretchen, Nag, Purba, Deans, Andrew J., Khanna, Kum Kum |
| Předmět: |
|
| Zdroj: |
Nature Communications; 5/26/2020, Vol. 11 Issue 1, p1-18, 18p |
| Abstrakt: |
Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA polymerase I transcription of ribosomal RNA genes (rDNA), induces replication stress and activates the DNA damage response. CX-5461 co-operates with PARPi in exacerbating replication stress and enhances therapeutic efficacy against homologous recombination (HR) DNA repair-deficient HGSOC-patient-derived xenograft (PDX) in vivo. We demonstrate CX-5461 has a different sensitivity spectrum to PARPi involving MRE11-dependent degradation of replication forks. Importantly, CX-5461 exhibits in vivo single agent efficacy in a HGSOC-PDX with reduced sensitivity to PARPi by overcoming replication fork protection. Further, we identify CX-5461-sensitivity gene expression signatures in primary and relapsed HGSOC. We propose CX-5461 is a promising therapy in combination with PARPi in HR-deficient HGSOC and also as a single agent for the treatment of relapsed disease. Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and overcomes PARPi resistance in PDX models of HGSOC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
